Introductory

Gene Therapy Implementation - A Conversation with Dr. Lishel Horn

Histopathological characterization of immune-mediated hepatocellular injury following gene therapy in hemophilia

Durable efficacy and safety in responders: 5-Year post hoc end-of-study analysis of etranacogene dezaparvovec in the phase 3 HOPE-B trial

Elucidating the Mechanism Behind the AAV-Derived Factor VIII Assay Discrepancy

Relationship Between Transgene-Produced FVIII and Bleeding Rates 2 Years After Gene Transfer With Valoctocogene Roxaparvovec: Results From Gener8-1

Using the World Federation of Haemophilia Gene Therapy Registry for the Long-term Follow-up of Haemophilia Patients Treated with Gene Therapy

Preparing Treatment Centers for Administration

Importance of Monitoring Individuals With Hemophilia for Safety and Efficacy in the Short Term and Long Term

Gene Therapy in Hemophilia Ongoing and Future Research and What to Expect

Gene Therapy for Hemophilia A and B Compared to Available Treatments

Patient Perspectives for Hemophilia in Gene Therapy

Gene Therapy as a Global Solution

Monthly Roundup

Interactive Webinars

Podcasts

Conference Coverage

Highlights From the 17th Annual Congress of EAHAD

Highlights From the 65th ASH Annual Meeting and Exposition

Highlights From the ESGCT 30th Annual Congress

Highlights From the 31st Congress of ISTH

Highlights From the 32nd Congress of ISTH

Gene Therapy Illustrated Clinical Trials

Microlearning

Back To Top
Image

About

Supported through educational grants from BioMarin, CSL Behring, Pfizer Inc., Roche, and Spark Therapeutics

Essential SSL